Company Overview of Mallinckrodt LLC
Mallinckrodt LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions. It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems. It serves customers in the United States and internationally. The company was founded in 1867 and is based in St. Louis, ...
675 McDonnell Boulevard
St. Louis, MO 63042
Founded in 1867
Key Executives for Mallinckrodt LLC
Mallinckrodt LLC does not have any Key Executives recorded.
Mallinckrodt LLC Key Developments
IGI, Laboratories, Inc. Enters into Non-Exclusive License with Mallinckrodt LLC and Nuvo Research Inc
Jun 26 14
IGI Laboratories Inc. announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research Inc. to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM
May 1 14
Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China.
Nuvo Research Inc. Announces Lawsuit Against Mallinckrodt
Aug 21 13
Nuvo Research Inc. announced that the company has commenced legal action against Mallinckrodt Inc. (Mallinckrodt) by filing a Complaint in the United States District Court for the Southern District of New York. The complaint asserts that Mallinckrodt has breached its contractual obligations to Nuvo as set out in a Licensing Agreement dated June 15, 2009 pursuant to which Nuvo licensed to Mallinckrodt the rights to market and sell Pennsaid and Pennsaid 2% in the United States. The complaint asserts that Mallinckrodt breached the license agreement in several respects. Most significantly, Mallinckrodt willfully failed to conduct certain clinical studies required under the contract that are critical to regulatory approval, marketing and sales of Pennsaid 2% throughout the world. The complaint also alleges, amongst other things, that Mallinckrodt made significant errors in certain clinical studies for which it was responsible, failed to apply requisite efforts to commercialize Pennsaid in the United States and has willfully refused to pay the full milestone payments due to Nuvo under the license agreement. Nuvo is seeking damages of not less than $100 million and a declaration that it is entitled to terminate the license agreement which would result in the rights to market and sell Pennsaid and/or Pennsaid 2% in the United States reverting to Nuvo. Nuvo has not terminated the license agreement which continues in accordance with its terms pending the court's decision.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|